… The success of tyrosine kinase inhibitors (TKIs) in select patients with non–small-cell lung
cancer (NSCLC) has transformed management of the disease, placing new emphasis on …

… Lung adenocarcinoma can transform to small-cell lung cancer (SCLC) when resistance to
tyrosine kinase inhibitors (TKIs) develops. This phenomenon has repeatedly been described …

… the treatment of non–small cell lung cancer (NSCLC). The use of … development of EGFR
tyrosine kinase inhibitors, the discovery … of EGFR tyrosine kinase inhibitors (TKIs) in lung cancer. …

… -old woman with lung adenocarcinoma treated with EGFR tyrosine kinase inhibitor (TKI) …
of a secondary biopsy specimen revealed small-cell lung cancer (SCLC) that was sensitive to …

… Non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations
have mixed responses to tyrosine kinase inhibitors (TKIs). Intertumor heterogeneity in EGFR …

… with non–small cell lung cancer. Tyrosine kinase inhibitors have provided an illustrative
example of the successes in targeting oncogene addiction in cancer and the role of tumor-…

… lung carcinoma (NSCLC) has been transformed by the observation that lung adenocarcinomas
… (EGFR) are uniquely sensitive to EGFR tyrosine kinase inhibitors (TKI). In these patients, …

… To the best of our knowledge, this study evaluated the largest database in patients with lung
adenocarcinoma and EGFR G719X/L861Q/S768I mutations. In fact, the case number is far …

… [OMIM 131550]), a common genetic alteration in lung cancer, 4 renders potential sensitivity
to specific tyrosine kinase inhibitors (TKIs). The use of epidermal growth factor receptor (…

… Clinical development of other growth-related protein kinase inhibitors and efforts to understand
the biology of resistance to EGFR and ALK tyrosine kinase inhibition and strategies to …